Absci (ABSI) vs Nuvation Bio (NUVB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Absci (ABSI) has outperformed Nuvation Bio (NUVB) over the past year, gaining 146.5% versus a gain of 32.8%. Over five years, ABSI leads with a -13.3% price change compared with -49.1% for NUVB. Nuvation Bio is the larger company by market cap ($1.71 billion vs $1.58 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABSI | NUVB |
|---|---|---|
| Share price | $9.22 | $4.86 |
| Market cap | $1.58B | $1.71B |
| 1-day change | -10.22% | -0.41% |
| YTD return | +164.18% | -45.76% |
| 1-year return | +146.52% | +32.79% |
| 5-year return | -13.26% | -49.11% |
| EPS (TTM) | $-0.79 | $-0.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.06 | $9.75 |
| 52-week low | $2.24 | $3.36 |
| Distance from 52-week high | -23.52% | -50.15% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +56.18% | +167.49% |
| Average volume | 3.42M | 5.65M |
| Shares outstanding | 171.61M | 350.12M |
| Employees | 140 | 305 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABSI has outperformed NUVB by 113.7 percentage points over the past year.
About Absci
ABSI stock →Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 140 employees
About Nuvation Bio
NUVB stock →Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 305 employees
ABSI vs NUVB FAQ
Which is bigger, Absci or Nuvation Bio?
Nuvation Bio (NUVB) is larger, with a market capitalization of $1.71B compared with $1.58B for Absci (ABSI).
Which stock has performed better over the past year, ABSI or NUVB?
ABSI returned +146.52% over the past 12 months, compared with +32.79% for NUVB (price return, excluding dividends). Past performance does not predict future results.
Are Absci and Nuvation Bio in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Commercial Physical & Biological Resarch for Absci and Biotechnology: Pharmaceutical Preparations for Nuvation Bio.